Literature DB >> 15800682

Expression of p53, Ki-67 and Bcl-2 in parathyroid adenoma and residual normal tissue.

Tuvia Hadar1, Jacob Shvero, Eitan Yaniv, Eduard Ram, Itzhak Shvili, Rumelia Koren.   

Abstract

The aim of this study was to investigate the expression of Ki-67, bcl-2 and p53 in parathyroid adenomas and their residual rim of normal parathyroid tissue. Specimens from 26 parathyroid adenomas were studied by immunohistochemical analysis for Ki-67, bcl-2 and p53 expression. Positive findings were noted for p53 in 4 (15%) adenomas and none of the residual rims of normal parathyroid tissue (p = 0.055); for Ki-67 in 15 (56%) adenomas and none of the residual rims of normal parathyroid tissue (p = 0.00002); and for bcl-2 in 19 (73%) adenomas and 8 (31%) residual rims of normal parathyroid tissue (p < 0.01). The high rate of Ki-67 expression may indicate susceptibility of parathyroid adenomas to clonal proliferation. The weak immunoreactive expression of p53, combined with a relatively strong expression of bcl-2, may contribute to the characteristic slow progression of these tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15800682     DOI: 10.1007/BF03032405

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  31 in total

1.  BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.

Authors:  D M Hockenbery; M Zutter; W Hickey; M Nahm; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

Review 2.  [The occurrence and significance of apoptosis in tumors].

Authors:  Béla Szende
Journal:  Magy Onkol       Date:  2004-11-01

3.  The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors.

Authors:  M P Vargas; H I Vargas; D E Kleiner; M J Merino
Journal:  Mod Pathol       Date:  1997-01       Impact factor: 7.842

4.  Clonal loss of one chromosome 11 in a parathyroid adenoma.

Authors:  A Arnold; H G Kim
Journal:  J Clin Endocrinol Metab       Date:  1989-09       Impact factor: 5.958

5.  P53 as a marker of differentiation between hyperplastic and adenomatous parathyroids.

Authors:  Francesca Ricci; Pietro Luigi Mingazzini; Valeria Sebastiani; Emilio D'Erasmo; Claudio Letizia; Giorgio De Toma; Piero Luigi Alò
Journal:  Ann Diagn Pathol       Date:  2002-08       Impact factor: 2.090

6.  A comparative study of p53 immunoexpression in parathyroid hyperplasias secondary to uremia, primary hyperplasias, adenomas and carcinomas.

Authors:  M J Kayath; L C Martin; J G Vieira; L M Roman; V Nosé-Alberti
Journal:  Eur J Endocrinol       Date:  1998-07       Impact factor: 6.664

7.  p53 abnormalities in human parathyroid carcinoma.

Authors:  V L Cryns; M P Rubio; A D Thor; D N Louis; A Arnold
Journal:  J Clin Endocrinol Metab       Date:  1994-06       Impact factor: 5.958

8.  Proliferating cell nuclear antigen counts in formalin-fixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue.

Authors:  P A Dervan; H M Magee; C Buckley; D N Carney
Journal:  Am J Clin Pathol       Date:  1992-05       Impact factor: 2.493

9.  Immunohistochemical Analysis of the Cell Cycle-Associated Antigens Ki-67 and Retinoblastoma Protein in Parathyroid Carcinomas and Adenomas.

Authors:  Ricardo V. Lloyd; J. Aidan Carney; Jorge A. Ferreiro; Long Jin; Geoffrey B. Thompson; Jon A. Van Heerden; Clive S. Grant; Peter C. Wollan
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

Review 10.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

View more
  6 in total

1.  Molecular profiling of parathyroid hyperplasia, adenoma and carcinoma.

Authors:  Kristóf Árvai; Katalin Nagy; Helga Barti-Juhász; István Peták; Tibor Krenács; Tamás Micsik; Gyula Végső; Ferenc Perner; Béla Szende
Journal:  Pathol Oncol Res       Date:  2011-12-24       Impact factor: 3.201

Review 2.  Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.

Authors:  Romans Uljanovs; Stanislavs Sinkarevs; Boriss Strumfs; Liga Vidusa; Kristine Merkurjeva; Ilze Strumfa
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

3.  Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.

Authors:  Peter P Truran; Sarah J Johnson; Richard D Bliss; Thomas W J Lennard; Sebastian R Aspinall
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

4.  Selected markers of proliferation and apoptosis in the parathyroid lesions: a spatial visualization and quantification.

Authors:  Elzbieta Kaczmarek; Katarzyna Lacka; Przemyslaw Majewski; Pawel Trzeciak; Agnieszka Gorna; Donata Jarmolowska-Jurczyszyn; Andrzej Kluk
Journal:  J Mol Histol       Date:  2008-08-24       Impact factor: 2.611

Review 5.  Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.

Authors:  Benjamin D Zeitlin; Isaac J Zeitlin; Jacques E Nör
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

6.  Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas.

Authors:  Zuojie Luo; Jianling Li; Yinfen Qin; Yan Ma; Xinghuan Liang; Jing Xian; Decheng Lu; Minyi Wei; Jack Y Yang; Mary Qu Yang; Zhiheng He
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.